Vila-Farinas, Andrea
Pérez-Ríos, Mónica
Montes-Martínez, Agustín
Ahluwalia, Jasjit S-
Mourino, Nerea
Rey-Brandariz, Julia
Triñanes-Pego, Yolanda
Candal-Pedreira, Cristina
Ruano-Ravina, Alberto
Gómez-Salgado, Patricia
Miguez-Varela, Carmen
Tajes-Alonso, María
Loureiro-Fuentes, Isabel
Riesgo-Martín, Juan
Valverde-Trillo, Araceli
Fernández-Lema, Isabel
Rey-Arijón, Mercedes
Freiría-Somoza, Isabel
Rodríguez-Pampín, María
Varela-Lema, Leonor
Funding for this research was provided by:
Government Delegation for the National Plan on Drugs (2021I009)
Article History
Received: 15 October 2023
Accepted: 20 March 2024
First Online: 9 April 2024
Declarations
:
: The study was approved by the Research Ethics Committee of Lugo-Santiago (registration code 2021/402). All participants received a briefing note outlining the purpose and methodology of the study, and gave their prior written informed consent.
: Not Applicable.
: Jasjit Ahluwalia reports receiving sponsored funds for travel expenses as a speaker for the 2021 annual GTNF conference, and serving as a consultant for and has equity in Respira Technologies, a start-up company.